The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

In alternative embodiments, provided are therapeutic combinations, including products of manufacture and kits, and methods and uses thereof, using at least one potassium competitive acid blocker or acid pump blocker, or at least one inhibitor of H+/K+ ATPase, for treating, ameliorating, reversing and/or preventing (acting as a prophylaxis) a Helicobacter pylori (H. pylori) infection in an individual in need thereof.

In alternative embodiments, provided are therapeutic combinations, including products of manufacture and kits, and methods and uses thereof, using at least one potassium competitive acid blocker or acid pump blocker, or at least one inhibitor of H+/K+ ATPase, for treating, ameliorating, reversing and/or preventing (acting as a prophylaxis) a Helicobacter pylori (H. pylori) infection in an individual in need thereof.

In alternative embodiments, provided are therapeutic combinations, including products of manufacture and kits, and methods and uses thereof, using at least one potassium competitive acid blocker or acid pump blocker, or at least one inhibitor of H+/K+ ATPase, for treating, ameliorating, reversing and/or preventing (acting as a prophylaxis) a Helicobacter pylori (H. pylori) infection in an individual in need thereof.

The invention is directed to pharmaceutical compositions for suspending bismuth subsalicylate and methods of use thereof. Formulations of the present invention include at least three-gum systems to prevent the settling out of heavy particles in solution and do not include magnesium aluminum silicate. The pharmaceutical compositions may be used to treat gastrointestinal disorders.

The invention is directed to pharmaceutical compositions for suspending bismuth subsalicylate and methods of use thereof. Formulations of the present invention include at least three-gum systems to prevent the settling out of heavy particles in solution and do not include magnesium aluminum silicate. The pharmaceutical compositions may be used to treat gastrointestinal disorders.

Veterinary compositions comprising an essential oil such as parsley seed oil, lovage seed oil, and/or celery seed oil are disclosed. The essential oil is present in the form of a complex with a mixture of organic acids such as four acids of valeric acid, isovaleric acid, lactic acid, butyric acid, acetic acid, propionic acid, formic acid, benzoic acid, pelargonic acid, salicylic acid, malonic acid, citric acid, phthalic acid, tartaric acid, oxalic acid, malic acid, shikimic acid, fumaric acid, mandelic acid, cinnamic acid or derivatives thereof and a metal such as iron, bismuth, zinc, copper, manganese, cobalt, molybdenum, chromium, silver, gold, platinum, tungsten, germanium, tin, strontium, antimony, or salts or oxides thereof. The composition may be for the treatment and/or prevention of diseases caused by protozoa in animals. Methods of manufacturing the veterinary compositions are also disclosed.

Veterinary compositions comprising an essential oil such as parsley seed oil, lovage seed oil, and/or celery seed oil are disclosed. The essential oil is present in the form of a complex with a mixture of organic acids such as four acids of valeric acid, isovaleric acid, lactic acid, butyric acid, acetic acid, propionic acid, formic acid, benzoic acid, pelargonic acid, salicylic acid, malonic acid, citric acid, phthalic acid, tartaric acid, oxalic acid, malic acid, shikimic acid, fumaric acid, mandelic acid, cinnamic acid or derivatives thereof and a metal such as iron, bismuth, zinc, copper, manganese, cobalt, molybdenum, chromium, silver, gold, platinum, tungsten, germanium, tin, strontium, antimony, or salts or oxides thereof. The composition may be for the treatment and/or prevention of diseases caused by protozoa in animals. Methods of manufacturing the veterinary compositions are also disclosed.

An intramammary syringe contains a seal formulation for forming a physical barrier in the teat canal of a non-human animal. The syringe contains a reduced volume of from 0.25 ml to 2.0 ml of the seal formulation. The problem of ascending sealant during the dry period is solved.

An intramammary syringe contains a seal formulation for forming a physical barrier in the teat canal of a non-human animal. The syringe contains a reduced volume of from 0.25 ml to 2.0 ml of the seal formulation. The problem of ascending sealant during the dry period is solved.